Organ shortage requires policies and guidelines to aid organ allocation along the principles of urgency or utility. Identifying patients with significant benefit and withholding liver transplantation (LT) from patients too sick for transplantation are ongoing challenges, in particular in patients with malignancies. An arbitrary threshold of >50% 5-year overall survival (OS) is broadly considered a minimum standard for LT. In patients transplanted for intrahepatic cholangiocarcinoma (iCC), this was only achieved in select cases and when the tumor had a diameter of <2 cm. In patients with extrahepatic and hilar cholangiocarcinoma (CCC), strict selection criteria and combined preoperative radiotherapy/chemotherapy according to the Mayo protocol showed that acceptable longterm results can be achieved in a single high-volume center but are difficult to repeat elsewhere. Furthermore, only rigorously selected patients with neuroendocrine tumors (NETs) meeting the NET Milan criteria adopted by United Network for Organ Sharing can also have >50% 5-year OS. A prospective study in patients with unresectable colorectal cancer metastases in the liver has shown promising OS rates, but further prospective trials are warranted. Current evidence shows that none of the proposed expanded malignant criteria justify deviation of scarce donor organs to patients with hilar CCC, iCC > 2 cm, metastatic NET beyond NET Milan criteria, or metastatic colorectal cancer (CRC) outside clinical trials.
Utility of Liver Transplantation for Malignant Diseases
Listing, delisting, and allocation policies aim at selecting patients with a projected 5-year survival rate of over 50% and is referred to as rationing.
(1) As a result, allocation and distribution policies are not restricted to the best interest of an individual patient. To avoid ethical conflicts and litigations for physicians, treatment guidelines and allocation policies have been introduced by national transplant programs. (2) These recommendations and policies are based on empirical data with the aim to allocate donor livers to patients with the greatest need and best utility to society. (1) Recent reports suggest that selected patients with hepatobiliary malignancies despite advanced tumor stage but favorable tumor biology can have outcomes that are at least equivalent or even better than patients meeting conventional listing criteria. (3) For hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCC), Model for End-Stage Liver Disease (MELD) status exceptions (United Network for Organ Sharing [UNOS]) or standard exceptions (Eurotransplant [ET]) can be granted to patients with tumor stages within the Milan criteria for HCC (1 tumor < 5 cm or up to 3 tumors < 3 cm) or small intrahepatic cholangiocarcinoma (iCC) < 3 cm diameter and other favorable prognostic criteria. (4, 5) Expanded Criteria
Individual candidates with tumors exceeding these criteria or with neuroendocrine tumors (NETs) or Seehofer et al. (27) metastases from colorectal cancer (CRC) may be considered for transplantation by dint of "expanded criteria." Candidates may also receive organs from living donors or grafts allocated independently of MELD score ("rescue allocation"). Alternatively and for selected patients, "nonstandard" exceptions can be granted by the Regional Review Board (UNOS) or the Liver and Intestine Advisory Committee (ET) as an exceptional case request. (6) For liver transplantation (LT) in patients with "expanded" criteria, HCC has been extensively studied and has been discussed elsewhere. (7) The focus of this review is on LT for "expanded criteria" CCC, metastatic NETs, and colorectal cancer.
LT for CCC
The outcome of LT for CCC is reported mainly in retrospective single-center studies as summarized in Table 1 . If we adopt a threshold of >50% 5-year survival, this was achieved in 11 of the 37 trials reviewed and not reported as an endpoint in 20 studies. Predictors of favorable outcomes include early tumor stage, hilar tumor location, and neoadjuvant chemotherapy in combination with radiotherapy. (13, 19, 35) The main factor limiting wider application and the general applicability is the complexity of the specific protocol. Data on LT for hilar CCC were primarily generated in a single US center (Mayo Clinic, Rochester, MN), and an attempt to widen the number of participating centers and include centers with a lower specific case volume resulted in less favorable results. (33) Excellent outcomes have also been reported in 2 studies on LT recipients with small unilocular intrahepatic CCCs. (44, 45) The evidence suggests that expanding criteria for intrahepatic CCC beyond established UNOS and ET criteria will result in overall poor outcomes. Some patients with early stage hilar CCC may be suitable candidates for LT, but the selection criteria and the treatment protocol of the Mayo group should be adopted. Although a subgroup of patients with CCC can benefit from LT, patients with iCC >2 cm, multifocal disease, or hilar CCC without chemotherapy, radiation, and pretransplant staging operation (Mayo protocol) should not be considered for LT.
LT for Metastatic NETs
UNOS has published guidance for evaluation of patients with metastatic NETs in whom excellent SCHAEFER, ZOLLER, AND SCHNEEBERGER outcomes after LT can be achieved when strict selection criteria are applied. (6) Table 2 summarizes the posttransplant outcomes in patients with metastatic NET. The arbitrary 50% 5-year survival rate proposed as a minimum threshold for HCC has been achieved in 9 of 21 studies. On the basis of these results, UNOS policies were adopted to allow for individual application of nonstandard MELD status exception in UNOS. The only prospective single-center study in LT for NET yielded excellent results with a 5-year survival rate of >90%. The study, however, contrasts a body of literature indicating a recurrence rate of up to 57%. Favorable outcomes were more frequently reported after pre-LT chemotherapy and histologically low-grade tumors. (67) Accepting "expanded criteria" NET beyond the NET Milan criteria adopted by UNOS will result in poor outcomes and should therefore be avoided.
Nonresectability is a key criterion in patient selection for LT for NET liver metastasis. Because liver metastasis from NETs mostly develop in noncirrhotic livers, the definition of nonresectability remains a variable. Including modern techniques for liver augmentation and resection, chemoembolization, radiofrequency ablation, and selective internal radiotherapy, the number of patients who cannot be treated with 1 or a combination of these techniques is overall very small and decreasing. Reserving LT for liver failure in response to aggressive alternative surgical and nonsurgical treatment deserves consideration because the use of liver grafts for this indication could be limited when adopting the options.
LT for Liver-Only Metastatic Colorectal Cancer
Colorectal cancer with hepatic metastases may be curable, depending on the biological characteristics. In a prospective study of 21 patients transplanted for unresectable liver metastases, the 1-, 3-, and 5-year survival rates were 95%, 68%, and 60%, respectively. (68) Although encouraging, the efficacy needs to be replicated in a larger group of patients and more centers. Currently, 4 clinical trials are actively recruiting participants. (69) (70) (71) (72) Progress in interventional radiology, oncology, radiotherapy, and immunotherapy for the treatment of colorectal liver metastases makes it unlikely, however, that LT will evolve as a standard therapy even in patients with unresectable liver metastases. (3, 73) Critical Appraisal
Despite advances in LT for malignancy, a major obstacle remains: cancer is a systemic disease. Results in patients transplanted for HCC are encouraging, but in contrast to other malignancies under consideration for LT, extrahepatic metastases of HCC are rare. In contrast, the tumors discussed above are either a priori extrahepatic or are prone to have early lymphogenic or hematogenic metastatic spread. The most disillusioning example is the results of LT for iCC. The idea of improving the overall oncologic result is theoretically sound. However, the data do not indicate that this can actually be achieved. (24, 31) The prognosis of iCC can be improved by LT only in a minority of patients. Relatively good outcomes could be achieved in individuals with small, well-differentiated iCCs without vascular invasions. (74) Only iCCs with such characteristics in a cirrhotic liver with portal hypertension precluding resection are a possible indication for LT and in accordance with UNOS/Organ Procurement and Transplantation Network and ET criteria for MELD exception.
In contrast, patients listed for hilar CCC cannot be granted MELD exception and are therefore considered expanded criteria. The decision to resect or to transplant a patient with hilar CCC remains controversial. Results from controlled studies comparing outcomes after LT and resection are a prerequisite to decide if hilar CCC can be accepted as an expanded criterion for LT. (39) The exceptions to this are patients with borderline resectable hilar CCC and/or primary sclerosing cholangitis (PSC) as the underlying disease.
An attractive option to expand access to transplant is the Resection And Partial Liver Segment 2/3 Transplantation With Delayed Total Hepatectomy (RAPID) protocol. (75) With segments II and III from either a deceased or a living donor, recipients with oncologic conditions and lack of liver cirrhosis can be treated successfully. Although the surgical feasibility has been established, the perioperative risk and the selection criteria for patients to be included in such trials remains to be better established. Hopefully, initial success will translate into good longterm outcomes, justifying the risk.
Taken together, data from clinical trials show that none of the proposed expanded malignant criteria justify deviation of scarce donor organs to patients with hilar CCC, iCC > 2 cm, metastatic NET beyond NET Milan criteria, or metastatic CRC outside clinical trials.
Conclusion
LT remains the "last court of appeal" for patients with malignancies affecting the liver. Although some studies suggest that LT is an excellent treatment option in patients with advanced malignancy, LT cannot be generally recommended for such patients. In the interest of equity and fairness, the scarce resource must be responsibly allocated in accordance with national rules and legislation. We therefore advocate against systematically expanding criteria through individual MELD exemptions, but we hope that prospective controlled clinical trials with well-defined patient selection criteria will provide the evidence needed to expand LT criteria without putting overall good outcomes into jeopardy.
